These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Fecal markers: calprotectin and lactoferrin. Abraham BP; Kane S Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530 [TBL] [Abstract][Full Text] [Related]
4. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases]. Iijima H; Shinzaki S; Tsujii M; Takehara T Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015 [TBL] [Abstract][Full Text] [Related]
5. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. Schoepfer AM; Vavricka S; Zahnd-Straumann N; Straumann A; Beglinger C J Crohns Colitis; 2012 May; 6(4):412-8. PubMed ID: 22398068 [TBL] [Abstract][Full Text] [Related]
6. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108 [TBL] [Abstract][Full Text] [Related]
7. [Fecal calprotectin: a diagnostic tool for inflammatory bowel disease]. Fraga M; Godat S; Nydegger A; Moradpour D; Schoepfer AM Rev Med Suisse; 2012 Sep; 8(352):1669-70, 1672-3. PubMed ID: 22988727 [TBL] [Abstract][Full Text] [Related]
8. Canine inflammatory bowel disease: current and prospective biomarkers for diagnosis and management. Collins MT Compend Contin Educ Vet; 2013 Mar; 35(3):E5. PubMed ID: 23532922 [TBL] [Abstract][Full Text] [Related]
12. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327 [TBL] [Abstract][Full Text] [Related]
13. Review of fecal biomarkers in inflammatory bowel disease. Sutherland AD; Gearry RB; Frizelle FA Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035 [TBL] [Abstract][Full Text] [Related]
14. [Faecal calprotectin in inflammatory bowel diseases: review]. Kallel L; Fekih M; Boubaker J; Filali A Tunis Med; 2011 May; 89(5):425-9. PubMed ID: 21557177 [TBL] [Abstract][Full Text] [Related]
15. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Sipponen T Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984 [TBL] [Abstract][Full Text] [Related]
16. [Fecal calprotectin in the diagnosis of inflammatory bowel diseases]. Rodríguez-Moranta F; Lobatón T; Rodríguez-Alonso L; Guardiola J Gastroenterol Hepatol; 2013; 36(6):400-6. PubMed ID: 23434080 [TBL] [Abstract][Full Text] [Related]
17. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Gisbert JP; McNicholl AG Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356 [TBL] [Abstract][Full Text] [Related]
18. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796 [TBL] [Abstract][Full Text] [Related]
19. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Kolho KL; Raivio T; Lindahl H; Savilahti E Scand J Gastroenterol; 2006 Jun; 41(6):720-5. PubMed ID: 16716972 [TBL] [Abstract][Full Text] [Related]
20. Update of fecal markers of inflammation in inflammatory bowel disease. Judd TA; Day AS; Lemberg DA; Turner D; Leach ST J Gastroenterol Hepatol; 2011 Oct; 26(10):1493-9. PubMed ID: 21777275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]